Nurix Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Nurix Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2019 to Q4 2024.
  • Nurix Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending November 30, 2024 was -$739M, a 35.5% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 -$739M -$194M -35.5% Nov 30, 2024 10-K 2025-01-28
Q3 2024 -$680M -$177M -35.2% Aug 31, 2024 10-Q 2024-10-11
Q2 2024 -$631M -$165M -35.4% May 31, 2024 10-Q 2024-07-11
Q1 2024 -$587M -$145M -32.7% Feb 29, 2024 10-Q 2024-04-10
Q4 2023 -$545M -$144M -35.9% Nov 30, 2023 10-K 2025-01-28
Q3 2023 -$503M -$149M -41.9% Aug 31, 2023 10-Q 2023-10-12
Q2 2023 -$466M -$157M -51% May 31, 2023 10-Q 2023-07-13
Q1 2023 -$442M -$179M -67.8% Feb 28, 2023 10-Q 2023-04-13
Q4 2022 -$401M -$180M -81.7% Nov 30, 2022 10-K 2024-02-15
Q3 2022 -$355M -$171M -93.5% Aug 31, 2022 10-Q 2022-10-06
Q2 2022 -$309M -$154M -100% May 31, 2022 10-Q 2022-07-07
Q1 2022 -$263M -$135M -106% Feb 28, 2022 10-Q 2022-04-08
Q4 2021 -$221M -$117M -113% Nov 30, 2021 10-K 2023-02-09
Q3 2021 -$183M -$99.4M -119% Aug 31, 2021 10-Q 2021-10-14
Q2 2021 -$154M May 31, 2021 10-Q 2021-07-13
Q1 2021 -$128M Feb 28, 2021 10-Q 2021-04-13
Q4 2020 -$104M -$43.2M -71.5% Nov 30, 2020 10-K 2022-01-28
Q3 2020 -$83.8M Aug 31, 2020 10-Q 2020-10-14
Q4 2019 -$60.5M Nov 30, 2019 10-K 2021-02-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.